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Oestrogen receptor expression in ductal carcinoma in situ of the breast:
relationship to flow cytometric analysis of DNA and expression of the
c-erbB-2 oncoprotein
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Summary The expression of oestrogen receptor protein (ER) was examined in 151 cases of symptomatic or
screening detected pure ductal carcinoma in situ (DCIS) of the breast by immunocytochemical assay (ERICA),
in formalin-fixed paraffin-embedded tissue, with the monoclonal antibody H 222 (Abbott). Forty-eight
tumours (31.8%) of cases were ER positive. Twenty-seven (17.9%) of cases showed high level ER expression
and 21 (13.9%) of cases showed low level ER immunoreactivity. Significant associations of positive tumour
ER immunoreactivity and non-comedo architecture x2 = 6.76; (d.f. = 1): P<0.O01, small cell size x2 = 4.49;
(d.f. = 1): P = 0.034, higher S-phase fraction X2 = 4.71; (d.f. = 1): P = 0.03 and lack of c-erbB-2 protein
overexpression x = 7.96; (d.f. = 1): P <0.01 were identified. No significant associations of ER expression and
patient age, histological grade of necrosis in DCIS, or DNA ploidy were found. ER expression is detectable in
less than one third of symptomatic and screening detected cases of DCIS, implying that endocrine therapy of
DCIS may be a more appropriate form of management for morphological subtypes of DCIS which show
higher rates of oestrogen receptor expression, particularly those of non-comedo and small cell type.
Ductal carcinoma in situ (DCIS) of the breast has become
increasingly important as a result of breast screening, now
accounting for approximately 20% of screening detected
breast cancers. Previous studies of ER (oestrogen receptor)
expression in pure DCIS have been limited (Barnes &
Masood, 1990; Bur et al., 1992; Giri et al., 1989; Malafa et
al., 1990; Ronay et al., 1990) and of smaller size. Results of
ER status in DCIS in the literature have often been described
as a part of much larger series of symptomatic invasive
breast tumours. Previous studies have indicated that positive
ER status in DCIS is associated with certain morphological
subtypes of in situ mammary carcinoma (Barnes & Masood,
1990; Bur et al., 1992; Giri et al., 1989).
The management of DCIS is now the subject of several
ongoing clinical trials in Europe and the USA, some of
which include endocrine therapy as part of trial protocols
(Fentiman, 1990; 1992). Positive ER status in DCIS could
infer a possible survival advantage or a relatively lower
degree of biological tumour aggressiveness, and might also
predict response to hormonal therapy (Nicholson et al., 1991;
Robertson et al., 1992), in particular to tamoxifen.
ER is a nuclear protein which shows sequence specific
transcription regulatory activity. Recent studies have also
shown that in the absence of a ligand the human ER has
both constitutive activator and repressor functions. In the
absence of ligand ER can bind and repress activators of the
oestrogen response element of the ER gene (Tzukerman et
al., 1990).
ER expression has been extensively investigated in invasive
breast carcinoma by radioligand binding assay techniques
such as dextran coated charcoal assay (DCC), and sucrose
density gradient centrifugation, and more recently by techni-
ques such as the immunohistochemical oestrogen receptor
assay (ERICA) (Charpin et al., 1986; Nicholson et al., 1991;
Remmele et al., 1986; Robertson et al., 1992; Snead et al. (in
press); Walker et al., 1988). The development of ERICA
assays has been facilitated by the availability of well charac-
terised monoclonal antibodies to the ER protein. The results
of ERICA examination in frozen breast tumour tissue using
the monoclonal anti-ER antibody H222 (Abbott) compare
favourably with published data obtained by conventional ER
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techniques (Charpin et al., 1986; Remmele et al., 1986;
Walker et al., 1988).
Recently, utilising an enzyme pre-digestion step prior to
incubation with monoclonal anti-ER antibody, expression of
ER protein has been demonstrated in archival formalin-fixed
paraffin-embedded breast tumour tissue with comparable
results to ERICA performed on frozen sections of breast
tumour tissue stored at - 20°C, ER radioligand assays, or
immunoassays (Aasmundstad et al., 1992; Cheng et al., 1988;
Elias et al., 1990; Graham et al., 1991; Paterson et al., 1990;
Raymond & Leong, 1990; Snead et al. (in press); Wilbur et
al., 1992).
Pronase pre-digestion of tissue sections was utilised in
many of the studies of ER expression in formalin-fixed
paraffin-embedded breast tumour tissue to date (Aasmund-
stad et al., 1992; Cheng et al., 1988; Graham et al., 1991;
Raymond & Leong, 1990; Snead et al. (in press)). One study
employed pronase pre-digestion with repeated applications of
primary antibody (Elias et al., 1990). Equivalent results have
also been claimed for ERICA techniques applied to formalin-
fixed paraffin-embedded tissue that use DNase pre-digestion
of tissue sections (Paterson et al., 1990; Shintaku & Said,
1987) or protease pre-digestion (Barnes & Masood, 1990).
The presence of oestrogen receptor expression in invasive
breast carcinoma has been shown in some series to be
associated with low tumour grade, i.e. well differentiated
tumours (Walker et al., 1988). Positive ER status also tends
to predict a greater likelihood of response to endocrine
therapy (Nicholson et al., 1991; Robertson et al., 1992) and
may confer a small positive survival advantage as compared
to subgroups of patients with ER negative invasive car-
cinomas.
Our aim in this study was to examine the extent of ER
protein expression in DCIS and to relate ER expression to
morphological features of DCIS such as architecture, cellular
size and degree of necrosis, to clinical variables such as
patient age, and to flow cytometric analysis of DNA and
c-erbB-2 protein overexpression.
Methods
Patients
All the patients were under the care of one surgical team
(Prof. R.W. Blamey), at the University Department of
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Surgery, City Hospital, Nottingham, and presented as either
symptomatic DCIS, or DCIS detected via breast screening.
Histopathological classification ofDCIS
Tumours were classified on the basis of cell size and architec-
ture. Cell size and architecture were assessed subjectively by
two independent observers (D.N.P. and E.C.R.). Architecture
was assessed as pure comedo, solid, cribriform, mixed archi-
tectural pattern, cribriform, and micropapillary.
The majority of cases of small cell DCIS were of classical
cribriform and micropapillary subtypes, small cell size being
defined as cells with diameter up to 2-3 times that of the
diameter of surrounding benign breast epithelial cells, and
usually with nuclei up to 2.5 times the diameter of red blood
cells. Large cell DCIS was defined as DCIS with cell size
greater than 2-3 times that of normal mammary epithelial
cells, with larger nuclei which were more than 2.5 red cell
diameters in size. The subgroup of large cell DCIS included
classical comedo type DCIS, as well as some tumours with
pleomorphic nuclei showing either cribriform or micropapil-
lary architecture. For the purposes of statistical analysis all
tumours were then subdivided into two groups; large cell
(including the group of predominantly large cell DCIS), and
small cell (including the group comprising tumours of
predominantly small cell morphology).
A scoring system was utilised to indicate the degree of
intraluminal necrosis seen in all the types of DCIS, assessed
on a scale of 0-2. Tumours that showed no evidence of
necrosis in any of the tissue examined, or no more than one
or a few necrotic or desquamated cells within intraductal
lumina were classified as grade 0. This group included the
majority of classical cribriform, papillary, and micropapillary
subtypes. Tumours which showed lumina with moderate
amounts of necrotic cellular debris were classified as necrosis
grade 1, the latter group also included some tumours show-
ing cribriform or micropapillary architecture. Tumours which
showed substantial necrosis within lumina that contained
necrotic debris were classified as grade 2. These latter cases
were generally surrounded by large pleomorphic viable cells
in solid masses, the majority of cases being of comedo mor-
phology.
Immunocytochemistry (ERICA)
Representative blocks of formalin-fixed paraffin-embedded
tumour tissue from cases of symptomatic or screening
detected DCIS were taken and sections cut at 3 jim. The
sections were dewaxed in xylene and graded alcohol/water
mixtures and then immersed in a 0.5% hydrogen peroxide/
methanol mixture for 1 min to block endogenous peroxidase
activity. Pronase pre-digestion of tumour sections was then
performed by applying 0.02% pronase [Sigma P-6911] in
0.1 M phosphate buffered saline (PBS) at 37°C for 9 min
using a modification of the method first described by Cheng
et al. (1988).
After washing in running tapwater and rinsing in Tris
buffered saline (TBS) at pH 7.6, 1/5 normal swine serum in
TBS was then applied for 10 min to block non-specific bind-
ing sites of the anti-oestrogen receptor antibody, followed by
overnight incubation with primary anti-ER antibody (Abbott
H222, Abbott Ltd, Maidenhead, Berks, UK) diluted in equal
volumes with TBS, at room temperature, with a secondary
biotinylated sheep anti-rat antibody (Amersham RPN 1002,
Amersham, Bucks, UK) at a dilution of 1/100 in normal
swine serum/TBS for 30 min. An avidin-biotin immunoperox-
idase complex (ABC complex) was then utilised (Dako Ltd,
High Wycombe, Bucks, UK) with diaminobenzidine as a
chromogen (Abbott, Abbott Ltd, Maidenhead, Berks, UK).
Post-intensification was then performed with 0.5% copper
sulphate in 0.8% NaCl for 10 min. Sections were counters-
tained with ethyl green solution. The above method used on
formalin-fixed paraffin-embedded tumour tissue had been
previously shown in our laboratory to give optimal results
and correlation with ERICA examination of frozen tissue
sections in a series of 94 invasive breast carcinomas (Snead et
al., in press), drawn from the Nottingham/Tenovus Primary
Breast Carcinoma Series (Todd et al., 1987). Similar results
with pronase pre-digestion have also been obtained by others
(Aasmundstad et al., 1992; Wilbur et al., 1992).
ERICA status was assessed utilising an H score system
(McCarty et al., 1985). Positive immunostaining of the
nucleus is subdivided into three grades of intensity; 0
negative, 1 weak positive, 2 intermediate positive, and grade
3 strongly positive. The percentage ofmalignant cells staining
positively in each of the four categories is then assessed. The
H score is the sum of (% of grade 1 tumour cell nuclei +
twice % grade 2 tumour cell nuclei + thrice % grade 3
tumour cell nuclei); the possible range of the H score being
0-300.
In frozen tissue ERICA studies of invasive breast car-
cinoma the H score has been shown to be directly propor-
tional to quantitative ER status derived by biochemical assay
(Pertschuk et al., 1985). The score of all 151 tumours was
assessed by D.N.P. Cases of DCIS with tumour nuclei show-
ing at least focally positive ERICA immunostaining were
classified as ER positive for the purposes of statistical
analysis. H scores of below 50 indicated 'weak positivity' and
above 50 were taken to indicate 'strong ER positivity'. For
each batch of staining a tumour of known positive ER status
by biochemical ER assay was used as a positive control.
Flow cytometry
Thirty ytm sections of formalin-fixed paraffin-embedded
tumour tissue containing ample proportions of tumour were
analysed for DNA content following the method ofHedley et
al. (1985), as previously described (Locker et al., 1990). The
DNA index and S-phase fraction (S-pf) were derived. Histog-
rams were considered interpretable if the coefficient of varia-
tion was less than or equal to 8%. The DNA index was
calculated by measuring the ratio of the mode of the GO/GI
peak of the sample divided by the mode of the relative DNA
measurement of diploid GO/GI cells present in the sample.
The S-phase fraction was calculated using a modification of
the method of Baisch et al. (1975). Tumours were classified
as aneuploid if the DNA index was greater than or equal to
1.15. Tumours with a DNA index less than 1.15 were con-
sidered to be diploid.
c-erbB-2 overexpression
Overexpression of the c-erbB-2 oncoprotein was asssessed
using the affinity purified antibody 21N, a generous gift of
Dr W.J. Gullick, ICRF Molecular Oncology Group,
London, England. The antibody binds residues 1243-1255 of
the predicted amino acid sequence of the c-erbB-2 protein
(Venter et al., 1987). The tumours were stained with appro-
priate controls as previously described (Lovekin et al., 1991).
Positive membrane immunoreactivity indicated c-erbB-2
overexpression. Tumours that showed heterogenous mem-
brane c-erbB-2 staining were regarded as c-erbB-2 positive for
the purposes of statistical analysis. Some cases showed weak
cytoplasmic staining with 21N, but this was ignored for the
purposes of further analysis.
Results
Oestrogen receptor immunocytochemical assay (ERICA)
One hundred and fifty-one cases of pure DCIS were
examined. Some tumours showed positive nuclear ER stain-
ing of surrounding normal breast ducts and acini, as well as
of neoplastic breast tissue. A case of DCIS of comedo archi-
tecture showing typical positive nuclear ER staining is shown
in Figure 1. Little or no cytoplasmic ER staining was seen in
this series, and where noted was not analysed further.
Positive ER staining of benign breast acini adjacent to
tumour was noted in 36 of the 151 (23.8%) of cases158 D.N. POLLER et al.
Figure 1 DCIS of comedo architecture showing strong nuclear
immunoreactivity with the monoclonal antibody H222. x 130
magnification.
examined. One hundred and three cases which were ER
negative showed no evidence of ER staining in surrounding
normal breast ducts. In total, 48 tumours showed ERICA
positivity and 103 were ERICA negative.
Architecture
The results of ER analysis and architectural morphology of
DCIS are summarised in Table I. From this table it is evident
that DCIS of comedo architecture has a much lower fre-
quency of immunohistochemical ER expression than non-
comedo DCIS; x2 = 6.76; (d.f. = 1): P = 0.0093, and that
other architectural subtypes of DCIS have relatively equal
ER expression.
Cell size
Twenty-four of 57 (42.1%) cases of small cell type (including
the group of predominantly small cell pattern) were ERICA
positive as compared to 24 of 94 (25.5%) cases of large cell
(including predominantly large cell type); x2 = 4.49; (d.f. = 1):
P = 0.034, indicating a positive association of ERICA status
and small cell size (please see Table II). When the cases were
subdivided by H score into three groups, ER negative i.e. H
score = 0, ER weak positive i.e. H score 0 > 50, and ER
strong positive i.e. H score >50, 21 (13.9%) of cases showed
low level ER immunoreactivity and 27 (17.9%) of cases
showed high level ER expression.
Grade ofnecrosis in DCIS
Of the 151 cases examined 37 cases showed substantial i.e.
grade 2 necrosis, 63 showed grade 1 necrosis, and 51 showed
no evidence of necrosis, i.e. grade 0. The results are tabulated
in Table III. No association of ER status and grade of
necrosis was identified, X2 = 4.58; (d.f. = 2): P<0.101 (please
see Table III).
Age
Fifteen patients were less than 40 years in age, 31 were
40-49 years of age, 50 patients were 50-59 years of age, and
55 patients were greater than 60 years of age. Of the group
aged less than 40, seven (47%) were ER positive, aged
40-49, nine cases (29%) were ER positive, aged 50-59, 15
(30%) were ER positive, and aged 60-69, 17 (33%) were ER
positive. No significant association of ER status and patient
age was identified, X2 = 1.88; (d.f. = 3): P = 0.598 (please see
Table III).
DNA ploidy
DNA flow cytometry data was available in 101 of 151 cases.
No statistically significant association of DNA aneuploidy
(DNA index equal to or greater than 1.15) was identified
although there was a tendency towards DNA aneuploidy in
the subgroup of tumours that were ER positive, x2 = 3.05;
(d.f. = 1): P = 0.08 (please see Table IV).
S-phasefraction
S-pf could be derived from the DNA histograms in 80 cases.
Taking an arbitrary cut-off of 6%, with subdivision of the
tumours into two groups, 40 tumours had an S-phase frac-
tion less than 6% and 40 tumours S-pf greater than 6%. A
positive statistical association of higher S-phase and positive
ER status was identified, x2 = 4.71; (d.f. = 1): P = 0.03 in the
subgroup of tumours with S-pf greater than 6% (please see
Table IV).
Table I Oestrogen receptor status of DCIS and architecture
DCIS Immunohistochemical oestrogen receptor status
architecture Strongpos Weak pos Negative Totalpos (%)
Comedo 4 3 38 7 (16%)-
Solid 5 3 14 8 (36%)
Mixed 10 6 28 16 (36%)
Cribriform 7 9 21 16 (43%)
Micropapillary 1 0 2 1 (33%)
aX2 comedo/non-comedo DCIS = 6.76: (d.f. = 1); P = 0.0093 (signi-
ficant).
Table II Oestrogen receptor status of DCIS and cell size
Cell size
Immunohistochemical oestrogen receptor status
Strong pos Weak pos Negative Total pos (%)
Large cell 15 9 70 24 (25.5%)
Small cell 12 12 33 24 (42.1%)
aX2 =4.49; (d.f.
= 1); P = 0.034 (significant).
TableIII Oestrogen receptor status ofDCIS and relationship tograde
of necrosis and patient age
Grade of Oestrogen receptor Percentage
necrosis pos/neg ER positive
0 21/30 41.1%a
1 20/43 31.7%
2 7/30 18.9%
Oestrogen receptor Percentage
Patient age pos/neg ER positive
<40 7/8 46.6%b
40-49 9/22 29.0%
50-59 5/35 30.0%
>60 18/37 32.7%
aX2=4.58: (d.f.=2); P<0.101 (not significant). bX2= 1.88:
(d.f. = 3); P= 0.598 (not significant).
Table IV Oestrogen receptorstatusofDCISandrelationship to DNA
ploidy and S-phase fraction
Oestrogen receptor Percentage
DNA ploidy pos/nega ER positive
Diploid 18/44 29.0%
Aneuploid 18/21 46.1%
Oestrogen receptor Percentage
S-phase pos/negj ERpositive
Low 8/32 20.0%
High 17/23 42.5%
aX' = 3.05: (d.f. 1); P= 0.08 (notsignificant). bX=4.71: (d.f. = 1);
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c-erbB-2 overexpression
c-erbB2 data were available on 116 of the 151 cases. Fifty-six
tumours were c-erbB-2 negative and 60 tumours were c-erbB-2
positive. A significant association of positive ER status and
absence of c-erbB-2 overexpression was identified, X2 = 7.96;
(d.f. = 1): P<0.01.
Discussion
This study of ER expression in a large series of symptomatic
and screening detected DCIS, the largest published to date,
has shown that expression of ER protein is present in
approximately 30% of cases of pure ductal carcinoma in situ
of the breast. The frequency of ER expression in DCIS is
much lower than that seen in invasive carcinoma, which is
approximately 60% of cases in most series.
The ERICA method employed is easily applicable to
routine formalin-fixed paraffin-embedded tumour tissue,
much enhancing its potential utility to pathologists and
clinicians alike, and also allowing retrospective analysis of
ER status in archival breast biopsy material. Our published
method differs from that first published by Cheng et al.
(1988) in that a 1/5 dilution of normal swine serum in TBS
rather than 1 mM levamisol is utilised to block non-specific
antibody binding sites.
Biochemical ER assessment is not practicable on a sub-
stantial number of surgically excised biopsies of DCIS, due
to the limited amount of tumour tissue available, and prob-
lems in tumour tissue sampling. Tumour sampling of DCIS
for assessment of ERICA on frozen tissue is also difficult or
often impossible, particularly in situations where assessment
of excision margins is important, as in breast conservation
treatment, or diagnostic marker biopsies of lesions detected
by breast screening. Screening detected cases of DCIS tend to
be much smaller than symptomatic cases and biochemical
assays are therefore not practicable in the majority of these
cases. Direct visualisation of ER by immunocytochemistry
allows microscopic assessment of ER in tumour tissue only,
and avoids the problems of tumour sampling inherent in
biochemical ER receptor assays.
As ER expression is also present in benign mammary
epithelial tissue, the presence of significant ER receptor ex-
pression in benign breast tissue adjacent to invasive tumours
which in some cases are ER negative (Walker et al., 1992)
could be a potential cause some false positive biochemical
ER assay results.
Our finding of a relatively lower frequency of ER expres-
sion in comedo and large cell DCIS as compared to small cell
DCIS is consistent with three earlier studies (Barnes &
Masood, 1990; Bur et al., 1992; Giri et al., 1989). Barnes and
Masood (1990) using DNase I protease pre treatment of
archival tissue sections, prior to incubation with ER
antibody, found a lower frequency of ER expression in com-
edo DCIS, as compared to non-comedo DCIS, with all cases
of atypical hyperplasia examined showing positive ER stain-
ing, albeit with a higher total frequency of ER expression in
DCIS in their series. The largest series of ER in DCIS
published to date (Bur et al., 1992), used pronase pre-
digestion of archival tissue sections, and also showed a
greater frequency of immunohistochemical ER expression in
non-comedo DCIS, seen in 55 of 60 tumours (91% of cases),
as compared to 20 of 35 cases of comedo DCIS (57% of
cases). Bur et al. also found a similar relationship of greater
frequency of ER expression and small or intermediate cell
size, and lack of necrosis. Giri et at. (1989) identified ER
expression in three of 18 (17% of cases) of comedo DCIS,
and 15 of 27 (55% of cases) of cribriform/papillary DCIS
giving an overall figure of 42-45% of cases showing
'significant' ER positivity. A further immunohistochemical
study of 14 cases of DCIS identified ER expression in eight
of 14 tumours (57% of cases) (Malafa et al., 1990). No
indication was made in the latter ERICA study as to the
type, if any, of enzymatic pre-digestion step employed, and
no comment was made regarding ERICA status and his-
tological subtype of DCIS. Another study conducted using
frozen tissue also examined ER status by ERICA within the
intraductal component of 77 invasive breast carcinomas. A
high percentage of tumours showed positive ER expression
within the intraductal component, totalling 58 (72%) ofcases
examined (Ronay et al., 1990).
The largest series of ER in DCIS published to date (Bur et
al., 1992) identified an overall ER positivity rate in DCIS and
lobular carcinoma in situ of 80%, comprising 38 cases of
pure DCIS, and 62 cases of invasive carcinoma, with an
associated in situ component. Bur et al. used an equivalent
immunohistochemical technique to ourselves, with pronase
pre-digestion of tissue sections prior to application of Abbott
H222 ER antibody. In this series 25 of 38 (65%) of cases of
pure DCIS were ER positive, as compared with 57 of 62
(91%) of cases of invasive carcinoma in which ER
immunoreactivity was assessed in the in situ component. ER
positivity of the in situ component was identified in
significantly greater number of invasive tumours as compared
to pure DCIS.
As 77 of 100 cases in Bur et al.'s series were from outside
the institution, to allow for potential differences in tissue
fixation, all cases of ER negative DCIS or invasive car-
cinoma with in situ disease where ER staining was not pre-
sent in adjacent normal breast lobules were excluded from
the series. It is possible that some cases of ER negative DCIS
were excluded from this latter series, most probably large cell
and comedo DCIS, particularly as other studies of ER ex-
pression in benign tissues adjacent to breast tumours show
ER expression in up to 46% of cases in benign tissues
adjacent to tumours which are ER negative (Walker et al.,
1992). We identified positive ER staining of benign breast
acini adjacent to tumour in 36 of the 151 (24%) of cases
examined, and 102 of our cases which were ER negative
showed no evidence of ER staining in surrounding normal
breast ducts. The differences in frequency of ER expression
between the various published series may, therefore, be
explained by differences in immunohistochemical technique,
and differences in cases selected for inclusion.
As all cases in this series were pure DCIS, the differences
in frequency of ER expression may be, at least in part, due
to the fact that all our cases were pure ductal carcinoma in
situ, with lobular carcinoma in situ and intraduct components
of invasive carcinomas being excluded. This may well reflect
differences in the biology of pure in situ DCIS, as compared
to tumours that have undergone clonal selection to form a
more aggressive tumour, prior to development of invasive
disease (Nowell, 1976).
No significant associations of ER expression and DNA
aneuploidy could be identified in our study. There was a
significant association ofhigher S-phase fraction and positive
ER status, this is difficult to explain, given our current
knowledge of the biology of breast cancer. No other study
has examined the relationship of ER and DNA flow
cytometry in DCIS to our knowledge. We noted a similar
inverse relationship of positive ER status and absence of
c-erbB-2 overexpression in DCIS, as has also been described
by ourselves and others in invasive breast carcinoma
(Lovekin et al., 1990).
The major clinical importance of this study is the
confirmation in a large series of pure DCIS of earlier more
limited studies showing that expression of ER is present in a
proportion only, of cases of in situ mammary carcinoma,
with implications for endocrine therapy of DCIS. This study
shows a lower frequency of ER expression than other pub-
lished series. The potential importance of ER expression in
therapy of DCIS will require further prospective and retro-
spective analyses of ER in DCIS to establish the role of ER
status in DCIS in predicting clinical response of DCIS to
adjuvant endocrine therapy. Endocrine adjuvant therapy of
DCIS is now an integral component of several clinical trials
of DCIS, both in the UK (Fentiman, 1992) and the USA.
It is likely, however, that the mechanisms controlling oest-
rogen receptor mediated signal transduction are complex,160 D.N. POLLER et al.
and that the absence of immunohistochemically detectable
ER may not necessarily preclude patient response to endo-
crine therapy in some instances, as is the case in invasive
breast carcinoma.
Comedo DCIS and subtypes of DCIS showing significant
tumour cell necrosis have been shown to have a shorter time
to local recurrence after breast conservation treatment. Com-
edo DCIS and large cell DCIS have a relatively lower fre-
quency of ER expression than small cell DCIS. Comedo
DCIS has a higher cellular proliferation fraction as measured
by thymidine labelling index (TLI) (Meyer, 1986), or flow
cytometric S-phase fraction (Locker et al., 1990). Comedo
DCIS shows c-erbB-2 oncoprotein overexpression in a higher
proportion of cases than non-comedo DCIS (Van de Viijver
et al., 1988; Locker et al., 1990).
The confirmation of a relatively higher frequency of ER
expression in small cell DCIS and the same inverse relation-
ship of lack of ER expression and c-erbB-2 protein overex-
pression in DCIS as seen in invasive breast carcinoma sug-
gests evidence for homology of ER and c-erbB-2 protein
expression in both forms of mammary carcinoma. This latter
relationship appears conserved in neoplastic progression from
in situ to invasive disease.
This study addresses one major aspect of ER in DCIS;
namely the immunohistochemical expression of oestrogen
receptor. Subsequent prospective studies of ER status in
DCIS should also take account of the menopausal status of
patients, and the role of timing of surgery within the men-
strual cycle, both of which may possibly influence the ER
status of invasive breast tumours and their response to treat-
ment. This data was not available in our retrospective series.
The lower frequency of ER expression in pure DCIS as
compared to that in invasive disease may provide an avenue
for investigation of the function of oestrogen receptor in the
neoplastic progression of mammary carcinoma from in situ
to invasive malignancy.
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